NIOX Group plc, a global leader in fractional exhaled nitric oxide (FeNO) testing, has announced the launch of NIOX PRO®, its next-generation FeNO testing device designed to support healthcare professionals in the diagnosis and management of asthma, COPD and other inflammatory airway diseases.
Building on the proven clinical performance of NIOX VERO®, NIOX PRO® has been developed in collaboration with healthcare professionals from across the respiratory care pathway. The new device delivers the accuracy, and reproducibility clinicians expect from NIOX®, while introducing enhanced usability, connectivity and portability features.
FeNO testing is increasingly recognized as an important tool in asthma care, providing healthcare professionals with an objective biomarker of type 2 airway inflammation at the point of care.
NIOX PRO® represents the next step in our mission to improve access to FeNO testing and support better respiratory care worldwide. Developed with direct input from healthcare professionals, NIOX PRO® combines the trusted performance of NIOX® technology with new features designed to streamline workflows and enhance the user experience."
Jonathan Emms, CEO, NIOX®
Among the key advancements of NIOX PRO® are improved connectivity capabilities, including support for cloud-based data management through the newly developed NIOX Cloud™ application.
As healthcare systems continue to prioritize earlier diagnosis, personalized treatment and efficient management of respiratory diseases, NIOX PRO® has been developed to help clinicians integrate FeNO testing more easily into routine practice.
The launch marks an important milestone for NIOX®, which pioneered commercial FeNO testing in 1998, and has helped establish FeNO as a widely adopted biomarker in respiratory medicine.